Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.

Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ.

Nature. 2003 Sep 25;425(6956):407-10.

2.

Therapeutic and diagnostic implications of Hsp90 activation.

Kamal A, Boehm MF, Burrows FJ.

Trends Mol Med. 2004 Jun;10(6):283-90. Review.

PMID:
15177193
3.

Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.

Stravopodis DJ, Margaritis LH, Voutsinas GE.

Curr Med Chem. 2007;14(29):3122-38. Review.

PMID:
18220746
4.

[Heat shock protein 90: novel target for cancer therapy].

Chen Y, Ding J.

Ai Zheng. 2004 Aug;23(8):968-74. Review. Chinese.

PMID:
15301726
5.

Hsp90: an emerging target for breast cancer therapy.

Beliakoff J, Whitesell L.

Anticancer Drugs. 2004 Aug;15(7):651-62. Review.

PMID:
15269596
6.

[Molecular chaperone HSP90 as a novel target for cancer chemotherapy].

Miyata Y.

Nihon Yakurigaku Zasshi. 2003 Jan;121(1):33-42. Review. Japanese.

PMID:
12617036
7.

Hsp90 as a therapeutic target in prostate cancer.

Solit DB, Scher HI, Rosen N.

Semin Oncol. 2003 Oct;30(5):709-16. Review.

PMID:
14571418
8.

Hsp90 inhibitors as novel cancer chemotherapeutic agents.

Neckers L.

Trends Mol Med. 2002;8(4 Suppl):S55-61. Review.

PMID:
11927289
9.

Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.

Workman P.

Cancer Lett. 2004 Apr 8;206(2):149-57. Review.

PMID:
15013520
10.

HSP90 as a new therapeutic target for cancer therapy: the story unfolds.

Maloney A, Workman P.

Expert Opin Biol Ther. 2002 Jan;2(1):3-24. Review.

PMID:
11772336
11.

Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.

Tsutsumi S, Neckers L.

Cancer Sci. 2007 Oct;98(10):1536-9. Epub 2007 Jul 23. Review.

12.
13.

Altered Hsp90 function in cancer: a unique therapeutic opportunity.

Bagatell R, Whitesell L.

Mol Cancer Ther. 2004 Aug;3(8):1021-30. Review.

14.

Strategies for stalling malignancy: targeting cancer's addiction to Hsp90.

Prodromou C.

Curr Top Med Chem. 2009;9(15):1352-68. Review.

PMID:
19860736
15.

Effectiveness of hsp90 inhibitors as anti-cancer drugs.

Xiao L, Lu X, Ruden DM.

Mini Rev Med Chem. 2006 Oct;6(10):1137-43. Review.

PMID:
17073714
16.

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.

Powers MV, Workman P.

Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. Review.

18.

Heat shock protein and proteasome targeting agents.

Takimoto CH, Diggikar S.

Hematol Oncol Clin North Am. 2002 Oct;16(5):1269-85. Review.

PMID:
12512392
19.

Overview: translating Hsp90 biology into Hsp90 drugs.

Workman P.

Curr Cancer Drug Targets. 2003 Oct;3(5):297-300. Review.

PMID:
14529382
20.

Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

Chiosis G, Caldas Lopes E, Solit D.

Curr Opin Investig Drugs. 2006 Jun;7(6):534-41. Review.

PMID:
16784024

Supplemental Content

Support Center